- Home
- SA vs VCYT Comparison
SA vs VCYT Comparison
Compare SA & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SA
- VCYT
- Stock Information
- Founded
- SA 1979
- VCYT 2006
- Country
- SA Canada
- VCYT United States
- Employees
- SA N/A
- VCYT N/A
- Industry
- SA Precious Metals
- VCYT Medical Specialities
- Sector
- SA Basic Materials
- VCYT Health Care
- Exchange
- SA Nasdaq
- VCYT Nasdaq
- Market Cap
- SA 2.7B
- VCYT 2.9B
- IPO Year
- SA N/A
- VCYT 2013
- Fundamental
- Price
- SA $22.04
- VCYT $36.15
- Analyst Decision
- SA
- VCYT Buy
- Analyst Count
- SA 0
- VCYT 10
- Target Price
- SA N/A
- VCYT $40.40
- AVG Volume (30 Days)
- SA 1.3M
- VCYT 746.8K
- Earning Date
- SA 11-12-2025
- VCYT 11-04-2025
- Dividend Yield
- SA N/A
- VCYT N/A
- EPS Growth
- SA N/A
- VCYT N/A
- EPS
- SA N/A
- VCYT 0.34
- Revenue
- SA N/A
- VCYT $479,129,000.00
- Revenue This Year
- SA N/A
- VCYT $14.52
- Revenue Next Year
- SA N/A
- VCYT $9.90
- P/E Ratio
- SA N/A
- VCYT $107.60
- Revenue Growth
- SA N/A
- VCYT 19.91
- 52 Week Low
- SA $9.40
- VCYT $22.61
- 52 Week High
- SA $29.31
- VCYT $47.32
- Technical
- Relative Strength Index (RSI)
- SA 43.50
- VCYT 58.04
- Support Level
- SA $21.67
- VCYT $35.19
- Resistance Level
- SA $24.16
- VCYT $36.37
- Average True Range (ATR)
- SA 1.24
- VCYT 1.21
- MACD
- SA -0.46
- VCYT -0.09
- Stochastic Oscillator
- SA 6.93
- VCYT 59.57
About SA Seabridge Gold Inc. (Canada)
Seabridge Gold Inc is a development stage company involved in the exploration, and development of gold properties sited in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, and Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.